The human immune response to Mycobacterium tuberculosis in lung and lymph node

2004 ◽  
Vol 227 (4) ◽  
pp. 463-486 ◽  
Author(s):  
Simeone Marino ◽  
Denise E. Kirschner
Tuberculosis ◽  
2016 ◽  
Vol 97 ◽  
pp. 108-117 ◽  
Author(s):  
Tao Chen ◽  
Zhenyan Li ◽  
Li Yu ◽  
Haicheng Li ◽  
Jinfei Lin ◽  
...  

1991 ◽  
Vol 59 (2) ◽  
pp. 665-670 ◽  
Author(s):  
D V Havlir ◽  
R S Wallis ◽  
W H Boom ◽  
T M Daniel ◽  
K Chervenak ◽  
...  

2020 ◽  
Vol 2 (2) ◽  
pp. 77-87
Author(s):  
Abdi Dzul Ikram Hasanuddin ◽  
Nanang Roswita ◽  
Ivan Virnanda Amu

Understanding the human immune response toward Mycobacterium tuberculosis infection is important for controlling its infection. Its transmission through the air consists of "droplets nuclei" containing TB bacilli. After initial infection, the human body will provide diverse immune responses and will determine different clinico-histopathologic finding. This response starts from innate immunity that consists of phagocytosis by distal alveolar macrophages or nasal microfold cells, then will be continued by dendritic cells to be transferred to mediastinal lymph nodes to induced adaptive immune responses. This response is mediated by cells through IFN- γ signaling which will enhance phagocytosis. If this response is effective, there will be a latent infection with an initial histopathological finding of caseosa granulomas and predominantly followed by chronic granulomas. In a few cases, it can be reactivated via the IL-10 activation pathway and exogenous factors, it will induce a great adaptive immune reaction and provide more severe clinico-histopathological manifestation. The existence of the human body's immune response to Mycobacterium tuberculosis, etiher innate or adaptive immunity will determine the clinical course and pathology that will occur.


2010 ◽  
Vol 17 (7) ◽  
pp. 1094-1103 ◽  
Author(s):  
Niaina Rakotosamimanana ◽  
Vaomalala Raharimanga ◽  
Soa Fy Andriamandimby ◽  
Jean-Louis Soares ◽  
T. Mark Doherty ◽  
...  

ABSTRACT The majority of healthy individuals exposed to Mycobacterium tuberculosis will not develop tuberculosis (TB), though many may become latently infected. More precise measurement of the human immune response to M. tuberculosis infection may help us understand this difference and potentially identify those subjects most at risk of developing active disease. Gamma interferon (IFN-γ) production has been widely used as a proxy marker to study infection and to examine the human immune response to specific M. tuberculosis antigens. It has been suggested that genetically distinct M. tuberculosis strains may invoke different immune responses, although how these differences influence the immune responses and clinical outcome in human tuberculosis is still poorly understood. We therefore evaluated the antigen-specific IFN-γ production responses in peripheral blood mononuclear cells from two cohorts of subjects recruited in Antananarivo, Madagascar, from 2004 to 2006 and examined the influence of the infecting M. tuberculosis strains on this response. The cohorts were sputum-positive index cases and their household contacts. Clinical strains isolated from the TB patients were typed by spoligotyping. Comparison of the IFN-γ responses with the spoligotype of the infecting clinical strains showed that “modern” M. tuberculosis strains, like Beijing and Central Asian (CAS) strains, tended to induce lower IFN-γ responses than “ancient” strains, like East African-Indian (EAI) strains, in index cases and their household contacts. These results suggest that new strains may have evolved to induce a host response different from that of ancient strains. These findings could have important implications in the development of therapeutic and diagnostic strategies.


2011 ◽  
Vol 18 (4) ◽  
pp. 676-683 ◽  
Author(s):  
Susanna Commandeur ◽  
Krista E. van Meijgaarden ◽  
May Young Lin ◽  
Kees L. M. C. Franken ◽  
Annemieke H. Friggen ◽  
...  

ABSTRACTTheMycobacterium bovisBCG vaccine is the only tuberculosis (TB) vaccine available, yet it provides limited protection against pulmonary TB in adults and fails to protect against TB reactivation. We hypothesized that immunity againstMycobacterium tuberculosis“resuscitation-promoting factors” (Rpfs), which are small bacterial proteins that promote proliferation of dormant mycobacteria, may be relevant in the human immune response toM. tuberculosis. In previous unpublished work, we found that Rpfs Rv0867c and Rv2389c induced gamma interferon (IFN-γ) production in the blood of TB patients' healthy household contacts in several different African populations. Here we examine these two dominant Rpf antigens in more detail and define the nature of the responding T-cell subsets. Multiparameter cytokine profiling showed that Rv2389c and, to a lesser extent, Rv0867c were recognized by mycobacterium-responsive healthy Dutch individuals; peptide-scanning revealed several epitopes, including a single immunodominant epitope in Rv2389c. Rv0867c and, to a lesser extent, Rv2389c Rpf-specific T-cell responses were maintained for decades in long-termM. tuberculosisnonprogressors. Prominent Rv0867c-specific double- and single-cytokine-producing CD8+T-cell subset responses were found, including a large population of CD8+effector memory and effector T-cell subsets. We conclude thatM. tuberculosisRpf antigens are important targets in the human immune response toM. tuberculosisand represent interesting TB vaccine candidate antigens.


2021 ◽  
Vol 27 (4) ◽  
pp. 571-572 ◽  
Author(s):  
Roberto Burioni ◽  
Eric J. Topol

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Diane Williamson

This review considers the steps required to evaluate a candidate biodefense vaccine or therapy as it emerges from the research phase, in order to transition it to development. The options for preclinical modelling of efficacy are considered in the context of the FDA’s Animal Rule.


1989 ◽  
Vol 21 (4) ◽  
pp. 386???392 ◽  
Author(s):  
LEONARD H. CALABRESE ◽  
SUSAN M. KLEINER ◽  
BARBARA P. BARNA ◽  
CHRISTINE I. SKIBINSKI ◽  
DONALD T. KIRKENDALL ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document